百健 BIIB

Mr. Christopher A. Viehbacher has extensive international experience in both large pharmaceutical companies and entrepreneurial biotech companies; he has served as President and Chief Executive Officer, Biogen Inc. (since 2022); Managing Partner, Gurnet Point Capital, a Boston based investment fund (2015 - 2022); Global Chief Executive Officer of Sanofi S.A. (2008 - 2014); and in various roles at GlaxoSmithKline (1984 - 2008); he previously served on the board of Pure Tech plc (2015 - 2023); his other roles include Trustee, Northeastern University; Board of Fellows, Stanford Medical School; and Braveheart Bio, Inc.; he holds a Bachelor of Commerce from Queen's University (Kingston, Canada).

Ms. Alexander has served as our Executive Vice President, Chief Legal Officer since April 2018. Prior to that, Ms. Alexander served as our Executive Vice President, Chief Legal and Corporate Services from March 2017 to March 2018, as our Executive Vice President, Chief Legal Officer and Secretary from December 2011 to March 2017 and as our Executive Vice President, General Counsel and Corporate Secretary from 2006 to December 2011. Prior to joining Biogen, Ms. Alexander served as the Senior Vice President, General Counsel and Corporate Secretary of PAREXEL International Corporation, a biopharmaceutical services company, from 2003 to January 2006. From 2001 to 2003 Ms. Alexander served as General Counsel of IONA Technologies, a software company. From 1995 to 2001 Ms. Alexander served as Counsel at Cabot Corporation, a specialty chemicals and performance materials company. Prior to that, Ms. Alexander was a partner at the law firms of Hinckley, Allen & Snyder and Fine & Ambrogne. Education- Wellesley College, B.A. and Boston University School of Law, J.D. On March 11, 2026, Biogen Inc. announced that Susan H. Alexander, Chief Legal Officer, will depart from the Company effective as of the end May, 2026.

Ms. Murphy has served as our Executive Vice President, Pharmaceutical Operations and Technology since February 2022. Prior to that, Ms. Murphy has held senior executive positions at Biogen, including most recently as our Senior Vice President, Head of Global Manufacturing & Technical Operations, from June 2019 to January 2022. In 2017, Ms. Murphy played a critical role during the successful spin-off of Biogen's hemophilia franchise, as the Vice President and Head of Technical Operations of Bioverativ responsible for clinical and commercial development, quality, regulatory, manufacturing and procurement. Prior to the spin-off Ms. Murphy was the General Manager and Head of Cambridge Site Operations at Biogen from May 2015 to December 2016. Prior to joining Biogen, Ms. Murphy was Executive Director, Head of Supply Chain at Amgen, a biopharmaceutical company, where her responsibilities included leadership of commercial manufacturing and technical operations. Ms. Murphy also held numerous technical and operational roles during her time at Amgen from 2001 to 2015 where she contributed significantly to various facility start-ups, business development integrations, strategic transformations and new product introductions. Prior to Amgen, Ms. Murphy held a variety of process development and engineering positions at Immunex Pharmaceuticals and the Monsanto Company. Education- University of Massachusetts Amherst, B.S. Engineering and Rensselaer Polytechnic Institute, M.S. Engineering and a Masters of Business Administration.

Dr. Singhal has served as our Executive Vice President and Head of Development since January 2023. Prior to that Dr. Singhal served as our Interim Head of Research and Development since 2021 in addition to serving as Head of Global Safety and Regulatory Sciences, including China and Japan Research and Development, since rejoining Biogen in 2020. Dr. Singhal was initially at Biogen from 2012 to 2018 and served in positions of increasing seniority as Vice President Clinical Trials Benefit-Risk Management, Global Head of Safety and Benefit Risk Management and as the Interim Co-lead and Senior Vice President of Global Development. Prior to her 2020 return to Biogen, Dr. Singhal served as Head of Research and Development and Manufacturing at Zafgen Inc. from 2019 to 2020. From 2008 to 2012 Dr. Singhal held roles at Vertex Pharmaceuticals, including Vice President, Medical Affairs. Dr. Singhal began her drug-development career at Millennium Pharmaceuticals, Inc. in 2005 and led benefit-risk management for Velcade and other compounds. Education- Harvard School of Public Health, M.P.H. in International Health and University of Mumbai, Doctor of Medicine (M.D.)

Ms. Kramer has served as our Chief Financial Officer since March 2025. Prior to that, Ms. Kramer served as our Senior Vice President, Chief Accounting Officer from December 2020 to February 2025 and from November 2018 to December 2020 as our Vice President, Chief Accounting Officer. Prior to joining Biogen, Ms. Kramer served as the Senior Vice President and Chief Accounting Officer of Hertz Global Holdings, Inc., a car rental company, from May 2014 to November 2018. Prior to that, Ms. Kramer was an audit partner at Deloitte & Touche LLP (Deloitte), a professional services firm, from 2007 to 2014, including serving in Deloitte's National Office Accounting Standards and Communications Group from 2007 to 2010. From 2005 to 2007 Ms. Kramer served as Chief Accounting Officer of Fisher Scientific International, Inc., a laboratory supply and biotechnology company, and from 2004 to 2005 Ms. Kramer served as Director, External Reporting, Accounting and Control for the Gillette Company, a personal care company. Ms. Kramer also held partner positions in the public accounting firms of Ernst & Young LLP and Arthur Andersen LLP. Ms. Kramer is a licensed CPA in Massachusetts. She is a member of the Massachusetts Society of CPAs and the American Institute of CPAs. Ms. Kramer previously served as a Board Member for the Center for Women & Enterprise from August 2020 to November 2024, the Massachusetts State Board of Accountancy from September 2011 to December 2015 and Probus Insurance Company Europe DAC from 2016 to 2018. Public Company Boards- Armata Pharmaceuticals, Inc., a biotechnology company. Education- Salem State University, B.S. Business Administration, Accounting.

Ms. Caroline D. Dorsa, Career Highlights: Executive Vice President (EVP) and Chief Financial Officer (CFO), Public Service Enterprise Group, Inc. (2009 - 2015); Senior Vice President (SVP) of Global Human Health, Strategy and Integration, Merck andCo., Inc. (2008 - 2009); SVP and CFO, Gilead Sciences, Inc. (2007 - 2008) and Various financial and operational positions at Merck andCo., Inc. including Vice President and Treasurer (1987 - 2007). Other Public Company Boards: Current: Illumina, Inc. (since 2010) and Duke Energy Corporation (since 2021). Prior - Intellia Therapeutics, Inc (2015 - 2023); Goldman Sachs Funds (2016 - 2021) and Public Service Enterprise Group, Inc. (2003 - 2009). Education: B.A. in History from Colgate University and M.B.A. in Finance and Accounting from Columbia University. On February 11, 2026, Caroline Dorsa, Chair of the Biogen Inc. Board of Directors announced that she would not stand for re-election to the Board at the 2026 Annual Meeting of Stockholders.

Mr. William A. Hawkins, III has significant executive and board leadership experience in the healthcare industry both domestic and international; he has served as Senior Advisor to EW Healthcare Partners, a life sciences private equity firm (since 2017); President and CEO, Immucor, a global leader in transfusion and transplant medicine (2011 - 2015); Chairman and CEO, Medtronic, Inc. (2002 - 2011); President and CEO, Novoste Corporation, an interventional cardiology company (1998 - 2001); he currently serves as Chair, Bioventus, Inc. (since 2016) and as a director of MiMedx Group, Inc. (since 2020); he previously served on the board of Avanos Medical, Inc. (2015 - 2021); his other roles and honors include Director, Virtue Labs, Enterra, Lacuna Medical, Cirtec Medical Corp. and Baebies, Inc., all private life sciences companies, and Member, National Academy of Engineering and AIMBE College of Fellows; he holds a B.Sc. in Electrical and Biomedical Engineering (dual) from Duke University and an M.B.A. from the University of Virginia's Darden School of Business.

Mr. Jesus B. Mantas has over 30 years of experience in global business operations, information technology, data science and artificial intelligence gained through global strategy and operating management roles across Europe, North America and Latin America; he has served as Global Managing Partner, IBM Global Business Services (2022 - 2025); held senior roles at IBM (2002 - 2022) including Global Managing Partner, Strategy, Innovation and Corporate Development; Global Managing Partner, IBM Business Consulting; General Manager, IBM Business Process Outsourcing; Managing Partner and General Manager, IBM Global Business Services Latin America; and Senior Partner, IBM Global Business Services; Partner, High Technology Practice, PricewaterhouseCoopers Consulting (1997 - 2002); Adjunct Professor, University of California Irvine, Graduate School of Management, Paul Merage School of Business (1997 - 2001); Second Lieutenant, Air Force of Spain (1993); he serves on the board of International Flavors and Fragrances Inc. (since 2025); he holds a B.S. in Telecommunications - Software Engineering from Universidad Politecnica de Madrid (Madrid, Spain), a Degree in Business Administration from Universidad Politecnica de Madrid (Madrid, Spain), and Corporate Governance from Harvard Business School.

On February 11, 2026, the Board elected Dr. Maria C. Friere to serve as Chair of the Board, effective after the Annual Meeting. Dr. Maria C. Freire, PhD, Career Highlights: President and Executive Director, the Foundation for the National Institutes of Health (NIH) (2012 - 2021); President and Director, Albert and Mary Lasker Foundation (2008 -2012); President and CEO, Global Alliance for TB Drug Development (2001 -2008) and Director of the Office of Technology Transfer, NIH (1995 - 2001). Other Public Company Boards: Current: Alexandria Real Estate Equities, Inc. (since 2012) and Exelixis, Inc. (since 2018). Other Boards and Awards: Science Board of the FDA; World Health Organization Commission on Intellectual Property Rights, Innovation and Public Health, United Nations Secretary General's High-Level Panel on Access to Medicines; Member, National Academy of Medicine and the Council on Foreign Relations and 2017 Gold Stevie Award for Woman of the Year, the U.S. Department of Health and Human Services Secretary's Award for Distinguished Service, the Arthur S. Fleming Award and the Bayh-Dole Award. Education: B.S. from the Universidad Peruana Cayetano Heredia (Lima, Peru) and Ph.D. in Biophysics from the University of Virginia.

Dr. Eric K. Rowinsky, M.D. has extensive research and drug development and regulatory experience and broad scientific and medical knowledge; he has served as President, Inspirna, a privately held life science company (since 2015), and Executive Chairman (2016 - 2021); Chief Medical Officer, Hummingbird Biotherapeutics (2020 - 2023); Chief Scientific Officer, Clearpath Development, Inc. (2016 - 2021); Head of R&D and Chief Medical Officer, Stemline Therapeutics (2012 - 2015); Chief Executive Officer, Primrose Therapeutics, Inc., a biotech start-up (2010 - 2011); Chief Medical Officer and Executive Vice President, ImClone Systems (2005 - 2010); he currently serves on the boards of Purple Biotech Ltd. (since 2019) and Verastem, Inc. (since 2017), and previously served on the board of Fortress Biotech Inc. (2010 - 2024); his other roles include Director of the Institute and Director of Clinical Research, Cancer Therapy & Research Center's Institute for Drug Development (1996 - 2004); Associate Professor of Oncology at the Johns Hopkins School of Medicine (1988 - 1996); Director, Scientific Counselors of the National Cancer Institute Level Panel on Access to Medicines; he holds a B.A. in Liberal Arts from New York University and an M.D. from Vanderbilt University School of Medicine.

Mr. Monish D. Patolawala has more than 25 years of experience leading financial operations and business for global industrial and healthcare companies; at Archer-Daniels Midland, he oversees the company's global finance and accounting, global business services, global technology and enterprise strategy functions; he has served as Chief Financial Officer, Archer-Daniels Midland (since 2024); President and Chief Financial Officer, 3M Company (2020 - 2024); Chief Financial Officer of GE Healthcare (2015 - 2020); and in a variety of roles of increasing responsibility at General Electric Company (1994 - 2020); he does not serve on any public company boards; he is a Chartered Accountant from the Institute of Chartered Accountants of India and a Cost and Works Accountant from the Institute of Cost and Works Accountants of India; he holds a Bachelor of Commerce from St. Joseph's College of Commerce (Bangalore, India).

Ms. Susan K. Langer has significant experience and knowledge of the biopharmaceutical industry and deep connections within the biotechnology, start-up and venture capital ecosystems; she has served as Founding President and Chief Business Officer, Souffle Therapeutics (since 2021); Founding President, Kojin Therapeutics (2020 - 2021); Chief Business Officer, Paratus Sciences (2021 - 2023); Director, Guava Partners (since 2021); Venture Partner, Old Silver VC LLC (2020 - 2023); and Head of Corporate Strategy and other roles at Biogen (2013 - 2019); she does not serve on any public company boards; she holds a B.A. in Science & Technology Studies from Cornell University.

Dr. Lloyd B. Minor, M.D. serves as the Dean of the Stanford University School of Medicine and Vice President Medical Affairs at Stanford University, where he is instrumental in establishing strategy across the Stanford Medicine enterprise, leading health and medicine matters at Stanford in research, clinical care and education; he has served as Carl and Elizabeth Naumann Dean of the Stanford University School of Medicine (since 2012); Vice President for Medical Affairs, Stanford University (since 2023); Provost and Senior Vice President for Academic Affairs, Johns Hopkins University (2009 - 2012); Director of the Department of Otolaryngology - Head & Neck Surgery, Johns Hopkins University (2003 - 2009); he serves on the board of Caris Life Sciences, Inc. (since 2021); he holds an Sc.B. from Brown University and an M.D. from Brown University.

Dr. Stephen A. Sherwin, M.D. has extensive knowledge of the life sciences industry through his advisory work in life sciences, and patient care and teaching in his specialty of medical oncology, as well as founding and leading life sciences companies; he has served as Clinical Professor of Medicine at the University of California, San Francisco (since 2010); Volunteer Attending Physician in Hematology-Oncology at the Zuckerberg San Francisco General Hospital (since 2010); Advisory Partner, Third Rock Ventures, LLC (since 2016); Chairman and Co-founder, Ceregene, a life sciences company acquired by Sangamo Biosciences (2001 - 2013); Chairman and Co-founder, Abgenix, Inc., an antibody company acquired by Amgen (1996 - 2006); Chief Executive Officer and Chairman, Cell Genesys, Inc., a life sciences company merged with BioSante Pharmaceuticals, Inc. (now ANI Pharmaceuticals, Inc.) (1994 - 2009); he currently serves on the boards of Neurocrine Biosciences Inc. (since 1999) and Innovent Biologics, Inc. (since 2025); he previously served on the boards of Epiphany Technology Acquisition Corp. (2022 - 2023), Bios Special Acquisition Corporation (2021 - 2023), and Aduro Biotech, Inc. (2015 - 2020); he holds a B.A. in Biology from Yale University and an M.D. from Harvard Medical School.

Professor Menelas Pangalos, PhD has over 30 years of experience researching and developing medicines gained through research and development roles across a number of pharmaceutical and biotechnology companies; he has served as Executive Vice President of Biopharmaceuticals R&D, AstraZeneca (2019 - 2024); Executive Vice President of Early R&D, AstraZeneca (2010 - 2018); Senior Vice President, Pfizer (2008 - 2010); Vice President Neuroscience, Wyeth (2003 - 2008); he is a Fellow of the Royal Society, the Academy of Medical Sciences, the Royal Society of Biology and Clare Hall, University of Cambridge; he serves on the board of Absci Corporation (since 2024); he holds a Bachelor of Science in Biochemistry and Molecular Biology from Imperial College London and a Ph.D. in Neuropharmacology from University College London.

Mr. Izzar has served as our Executive Vice President, Head of Global Product Strategy and Commercialization since July 2021. Prior to that Mr. Izzar served as our President for the Intercontinental Region, which includes Latin America, Australia, Asia, Japan, the Middle East and Africa, Turkey and Russia, and the Global Biogen Biosimilars Unit. Prior to joining Biogen, Mr. Izzar was a Country President for AstraZeneca in France, where his responsibilities included leadership for commercial and manufacturing operations. He held numerous roles at his time with AstraZeneca, including the position of Global Vice President of the Cardiovascular Franchise where he contributed significantly to the development of the franchise within the North American subsidiary, as well as in Europe and China. Prior to that, Mr. Izzar was Vice President Strategic Transformation, also, China Portfolio for CEO based in Shanghai and Vice President Commercial International covering China, Australia, Brazil, Russia, America Latin, Asia, Turkey, the Middle East and Africa. Education- University of Sherbrooke, Masters of Business Administration and Harvard Business School, Enterprise Executive Transformation Program.

Mr. Godbout has served as our Vice President, Chief Accounting Officer and Global Corporate Controller since March 2025. Prior to that, Mr. Godbout served as our Global Corporate Controller from October 2023 to February 2025 and Corporate Controller from September 2019 to October 2023 and has held roles of increasing seniority at the Company since 2007. Prior to joining Biogen, Mr. Godbout spent 10 years at PricewaterhouseCoopers LLP and he is a licensed CPA. Cornell University, B.S. Industrial and labor Relations and Northeastern University, M.S. Accounting and Masters of Business Administration.

Dr. Grogan has served as our Executive Vice President and Head of Development since October 2023. Dr. Grogan most recently served as the Chief Scientific Officer at Graphite Bio from 2021 to 2023 and ArsenalBio from 2019 to 2021, both cell and gene therapy companies. From 2004 to 2019 Dr. Grogan held several roles in increasing seniority at Genentech across Immunology and Immuno-oncology, covering research strategies and drug development across Rheumatoid Arthritis, Lupus, MS, Inflammatory Bowel Disease and Cancer. Education- Leiden University, Ph.D. in Immunology and University of Melbourne, B.Sc in Biochemistry and Pharmacology.

Dr. Keeney has served as our Executive Vice President and Head of Corporate Development since April 2023. Dr. Keeney brings more than 20 years of experience leading R&D, business development and strategy organizations at industry-leading companies within biotech and large pharma, Dr. Keeney most recently served as the Chief Executive Officer of NodThera, a clinical stage biotech company focused on chronic inflammation from 2018 to 2022. Prior to NodThera, Dr. Keeney was at Sanofi from 2014 to 2018 where he had responsibility for all of Sanofi Genzyme's business development activities, including early- and late-stage deals across therapeutic areas and modalities, successfully completing several significant transactions. From 2004 to 2013 Dr. Keeney worked at Johnson & Johnson where he held a number of business development roles with increasing responsibility and started his career at Lundbeck as a discovery scientist. Education- University of Nottingham, UK, Ph.D. in Neuropharmacology and University of Leeds, UK, BSc (Hons).

Dr. Gregory has served as our Executive Vice President and Chief Human Resources Officer since July 2017. Prior to joining Biogen, Dr. Gregory served as Executive Vice President and Chief Human Resources Officer at Shire PLC, a global specialty biopharmaceutical company, from February 2014 to April 2017. Prior to that, Dr. Gregory held executive-level human resources positions for several multinational companies across a variety of industries, including Dunkin' Brands Group Inc., a restaurant holding company, where she served as Chief Human Resource Officer, Novartis AG, a pharmaceutical company, where she was the division head of Human Resources for Novartis Vaccines and Diagnostics, Novartis Consumer Health and Novartis Institutes of BioMedical Research and Novo Nordisk A/S, a pharmaceutical company, where she served as Senior Vice President, Corporate People & Organization at the company's headquarters in Copenhagen, Denmark. Earlier in her career, Dr. Gregory held a variety of human resources generalist and specialist positions at BMS, a pharmaceutical company, and served as a consultant with Booz Allen & Hamilton, an information technology consulting company, in the area of organization change and effectiveness. Education- University of Massachusetts, B.A. Psychology and The George Washington University, Ph.D. Psychology.